---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-090702"
form_type: "8-K/A"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:34:15.422291+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma reports H1 2023 net loss of $33M; cash at $2.6M with going-concern doubt

## Summary
- Net loss of $33.0M for six months ended June 30, 2023 vs $7.6M loss in H1 2022.
- Cash fell to $2.6M as of June 30, 2023 from $9.7M at Dec 31, 2022.
- Accumulated deficit reached $507.9M; auditor notes substantial doubt about going concern.
- Convertible notes total $134.4M ($73.4M current + $60.9M non-current) as of June 30, 2023.
- Business combination with Priveterra closed July 21, 2023; now listed on NYSE as AEON.

## SEC filing metadata
- accession: 0001104659-23-090702
- form_type: 8-K/A
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000110465923090702/0001104659-23-090702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000110465923090702/tm2323141d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-090702
- JSON: https://secwatch.observer/filing/0001104659-23-090702.json
- Plain text: https://secwatch.observer/filing/0001104659-23-090702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.